Bronstein, Gewirtz & Grossman, LLC Is Investigating Acadia Healthcare Company, Inc. (ACHC) And Encourages Shareholders to Connect

NEW YORK CITY, NY / ACCESS Newswire / January 4, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Acadia Healthcare Company, Inc. ("Acadia Healthcare" or "the Company") (NASDAQ:ACHC). Investors who purchased Acadia Healthcare securities prior to February 28, 2020, and continue to hold to the present, are […]

Bronstein, Gewirtz & Grossman, LLC Encourages Methode Electronics, Inc. (MEI) Investors to Inquire about Securities Investigation

NEW YORK CITY, NY / ACCESS Newswire / January 4, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Methode Electronics, Inc. ("Methode Electronics" or "the Company") (NYSE:MEI). Investors who purchased Methode Electronics securities prior to December 2, 2021, and continue to hold to the present, are encouraged

Pomerantz LLP Updates Shareholders on Legal Action Brought Against Telix Pharmaceuticals Limited – TLX

NEW YORK CITY, NY / ACCESS Newswire / January 4, 2026 / Pomerantz LLP announces that a class action lawsuit has been filed against Telix Pharmaceuticals Limited ("Telix" or the "Company") (NASDAQ:TLX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are

Nework Celebrates Award-Winning 2025 and Looks Ahead to Smarter, Mobile Collaboration in 2026

LOS ANGELES, Jan. 04, 2026 (GLOBE NEWSWIRE) — Happy New Year! As 2026 begins, Nework extends warm wishes to customers, educators, partners, and technology enthusiasts everywhere. We sincerely thank you for your support in 2025–a year full of innovation, awards, and meaningful connections with our users. 2025 Highlights and Achievements In 2025, Nework strengthened its

Nework Celebrates Award-Winning 2025 and Looks Ahead to Smarter, Mobile Collaboration in 2026

Nework Celebrates Award-Winning 2025 and Looks Ahead to Smarter, Mobile Collaboration in 2026 Wishing everyone a prosperous new year, while continuing to empower home, education, and business users with innovative technology GlobeNewswire January 04, 2026 LOS ANGELES, Jan. 04, 2026 (GLOBE NEWSWIRE) — Happy New Year! As 2026 begins, Nework extends warm wishes to customers,

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. – LENZ

NEW YORK, NY / ACCESS Newswire / January 4, 2026 / Pomerantz LLP is investigating claims on behalf of investors of LENZ Therapeutics, Inc. ("LENZ" or the "Company") (NASDAQ:LENZ). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether LENZ and certain of its officers and/or directors

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aerovironment, Inc. – AVAV

NEW YORK, NY / ACCESS Newswire / January 4, 2026 / Pomerantz LLP is investigating claims on behalf of investors of Aerovironment, Inc. ("Aerovironment" or the "Company") (NASDAQ:AVAV). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Aerovironment and certain of its officers and/or directors have

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investorsâ?¯ofâ?¯agilon health, Inc. – AGL

NEW YORK, NY / ACCESS Newswire / January 4, 2026 / Pomerantz LLP is investigating claims on behalf of investors of� agilon health, Inc. ("agilon" or the "Company") (NYSE:AGL).��Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com�or 646-581-9980, ext.�7980. The investigation concerns whether agilon and certain of its officers and/or directors have engaged in

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc – MREO

NEW YORK, NY / ACCESS Newswire / January 4, 2026 / Pomerantz LLP is investigating claims on behalf of investors of Mereo BioPharma Group plc ("Mereo" or the "Company") (NASDAQ:MREO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Mereo and certain of its officers and/or

Scroll to Top